Date: Dec 18, 2014 Source: Canadian Private Equity (
click here to go to the source)
CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, has riased US $35 million in Series DD financing. Alberta Investment Management Corporation (AIMCo) participated in this round together with the company's existing investors.
Redwood City, California based CardioDx held a $21 million initial close in July.
"We are pleased to welcome AIMCo to the CardioDx family," said David Levison, CardioDx Founder, President and Chief Executive Officer. "AIMCo's support further validates our mission, and we are grateful for the continued commitment of our current investors, who recognize our expertise in developing genomic tests to address important unmet clinical needs for coronary artery disease."
The funds will enable CardioDx to broaden the commercial use of Corus CAD, the only clinically validated blood test that uses age, sex and gene expression to measure the likelihood of obstructive coronary artery disease in symptomatic patients, as well as to augment the company's research efforts to improve healthcare quality and efficiency through the development of additional genomic tests for coronary artery disease.
"The Corus CAD blood test is a validated decision-making tool to assist clinicians as they guide their patients through the diagnostic pathway for suspected obstructive coronary artery disease," added Chief Medical Officer, Mark Monane, M.D.
CardiDx investors include Kleiner Perkins Caufield & Byers, Mohr Davidow Ventures, TPG Biotech, Intel Capital, Pappas Ventures, DAG Ventures, Asset Management Group, GE Capital, Longitude Capital, JP Morgan, Acadia Woods Partners, Artiman Ventures, Bright Capital, and Temasek.
